knowledge -WSS

knowledge

author：fashion 2025-09-30 00:39:36 - browse：4624

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Meta looks to target Twitter with a rival app called Threads

hotspot

WSS

Grail is spending more than ever lobbying Congress

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

FDA approves first new drug developed for postpartum depression

Doctor appointment wait times are getting worse

Connecting traumatic brain injury and domestic violence

Living organ donors deserve priority status for transplants

explore

knowledge

entertainment

Medical records are filled with copy

Meta looks to target Twitter with a rival app called Threads

23andMe had bad news about my health. I wish a person had delivered it

A public health expert passes on football's full body collisions for youths

DIEP, the 'gold standard' of breast reconstruction, is under threat

Novo pauses ads for weight loss drug Wegovy amid demand

Hepatitis C has a cure — but many Americans still lack access to it

Listen: Biogen's messy board & Laronde's data problem

ChatGPT in medicine: STAT answers readers' burning questions

Connecting traumatic brain injury and domestic violence

hotspot

Millions may soon lose Medicaid when they don't have to

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

How to fix the rural physician shortage in the U.S.

Inside the fall of star MIT scientist David Sabatini

Inside the fall of star MIT scientist David Sabatini

Can food be medicine? And other questions about a new push

leisure time

hotspot

explore

hotspot